课题基金 / 基金详情

项目摘要

项目成果

STEPHANIE J LEE的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Project Summary/Abstract Over the last 15 years, the BMT CTN has effectively addressed key issues in HCT, including donor selection, choice of preparative regimens, prevention of post-transplant infection, prevention and treatment of graft- versus-host disease and the indications for HCT in the treatment of specific diseases, through the conduct of 37 clinical trials. The Fred Hutch Transplant Program has played an important role in the success of the BMT CTN since its inception, serving as one of its Core Clinical Centers. There are a number of features of the Fred Hutch Transplant Program that enhances its value as a Core Clinical Center. (1) The volume of clinical activity at the Hutch allows us to successfully recruit and enroll patients on BMT CTN clinical trials, including patients with rare diseases. The Hutch’s performance in reaching its BMT CTN accrual targets over the last four year has been rated by the BMT CTN as “outstanding.” (2) Our long and deep experience with HCT provides outstanding clinical outcomes. For the past 3 years running, we have exceeded the 95% confidence limits for survival as calculated by the center-specific outcomes measures of the Center for International Blood and Marrow Transplant Research (CIBMTR). (3) The faculty of the Fred Hutch Transplant Program includes a large number of investigators, all focused on various aspects of HCT. The breadth and depth of this group whose NIH funding includes 6 Program Projects, 26 RO1s, and numerous other awards, helps insure that we will continue to provide important scientific contributions to the network. Each year for the last 4 years, our group has been rated as “outstanding” by the BMT CTN for our scientific and administrative efforts. (4) The Fred Hutch has extensive experience with novel cell therapies including stem cell expansion, genetic engineering of T cells, and correction of inborn errors, which are areas of specific interest noted by the NHLBI and the NCI. (5) The faculty of the Fred Hutch have enthusiastically collaborated with other members of the BMT CTN to help achieve the networks research goals over the past funding periods and is committed to continuing to do so.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1016/s2352-3026(22)00206-x
发表时间: 2022-09
期刊: LANCET HAEMATOLOGY
影响因子: 24.7
作者: [DeZern, Amy E., Eapen, Mary, Wu, Juan, Talano, Julie-An, Solh, Melhem, Saldana, Blachy J. Davila, Karanes, Chatchada, Horwitz, Mitchell E., Mallhi, Kanwaldeep, Arai, Sally, Farhadfar, Nosha, Hexner, Elizabeth, Westervelt, Peter, Antin, Joseph H., Deeg, H. Joachim, Leifer, Eric, Brodsky, Robert A., Logan, Brent R., Horowitz, Mary M., Jones, Richard J., Pulsipher, Michael A.]
通讯作者: Pulsipher, Michael A.
DOI: 10.1200/jco.20.03380
发表时间: 2021-10-20
期刊: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
影响因子: --
作者: [Nakamura R, Saber W, Martens MJ, Ramirez A, Scott B, Oran B, Leifer E, Tamari R, Mishra A, Maziarz RT, McGuirk J, Westervelt P, Vasu S, Patnaik M, Kamble R, Forman SJ, Sekeres MA, Appelbaum F, Mendizabal A, Logan B, Horowitz M, Cutler C]
通讯作者: Cutler C
Blood & Marrow Clinical Trials Network- Hutchinson Center as Core Clinical Site
  • 批准号:
    10652543
  • 项目类别:
  • 资助金额:
    $21.12万
  • 财政年份:
    2022
  • 负责人:
    STEPHANIE J LEE
  • 依托单位:
Ustekinumab for Graft versus Host Disease Prevention (IND 144540)
  • 批准号:
    10644318
  • 项目类别:
  • 资助金额:
    $48.83万
  • 财政年份:
    2020
  • 负责人:
    STEPHANIE J LEE
  • 依托单位:
Ustekinumab for Graft versus Host Disease Prevention (IND 144540)
  • 批准号:
    10681200
  • 项目类别:
  • 资助金额:
    $86.23万
  • 财政年份:
    2020
  • 负责人:
    STEPHANIE J LEE
  • 依托单位:
Ustekinumab for Graft versus Host Disease Prevention (IND 144540)
  • 批准号:
    10252760
  • 项目类别:
  • 资助金额:
    $87.09万
  • 财政年份:
    2020
  • 负责人:
    STEPHANIE J LEE
  • 依托单位:
国内基金
海外基金
层出镰刀菌氮代谢调控因子AreA 介导伏马菌素 FB1 生物合成的作用机理
  • 批准号:
    2021JJ40433
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2021
  • 负责人:
    孙磊
  • 依托单位:
寄主诱导梢腐病菌AreA和CYP51基因沉默增强甘蔗抗病性机制解析
  • 批准号:
    32001603
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    24.0万元
  • 批准年份:
    2020
  • 负责人:
    段真珍
  • 依托单位:
AREA国际经济模型的移植.改进和应用
  • 批准号:
    18870435
  • 项目类别:
    面上项目
  • 资助金额:
    2.0万元
  • 批准年份:
    1988
  • 负责人:
    史树中
  • 依托单位: